Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Maybe There Will Be Some Hep C Patients Left

By Brian Orelli, PhD - Updated Apr 7, 2017 at 5:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sales of Vertex's Incivek decline substantially.

There's no doubt that the next generation of hepatitis C drugs will be better than the current offerings. While Vertex Pharmaceuticals' (Nasdaq: VRTX) Incivek and Merck's (NYSE: MRK) Victrelis add incremental efficacy to Roche's Pegasys and Merck's PegIntron, the next generation is likely to have cure rates well above the 79% that Incivek can produce without the need for Pegasys or PegIntron, which have nasty side effects.

But promising drugs from Gilead Sciences (Nasdaq: GILD), Bristol-Myers Squibb (NYSE: BMY), Abbott Labs (NYSE: ABT), and others are still years away. Until then, Merck and Vertex can treat as many patients as they can, leaving the 30% that aren't cured and the dwindling numbers of newly diagnosed patients for the next generation of drugs.

Unless, of course, the patients wait for the better medications that don't have those nasty side effects. Hepatitis C is a slow-acting disease. Infection can cause liver cancer and other liver problems, but it usually occurs years after patients become chronically infected. Doctors warehoused patients waiting for Incivek and Victrelis, which helped Incivek become an instant blockbuster.

Now it appears sales are slowing substantially.


Q2 2011 (in Millions)

Q3 2011 (in Millions)

Q4 2011 (in Millions)

Q1 2012 (in Millions)

Incivek* $75 $419.6 $456.8 $357
Victrelis** $21 $31 $87 $111

Source: Company releases.
*U.S. sales only.
**Global sales.

Merck sold just $67 million stateside, so while it may appear that Victrelis is cutting into Incivek sales, the take-home message is that sales have peaked.

Vertex says doctors aren't warehousing patients waiting for new treatments, but it seems pretty clear that they're not moving quickly to get patients treated, either. That's good news for drugmakers with hepatitis C drugs in the pipeline.

Is this bad news for Vertex? In the short term, absolutely. The difference between selling $1.5 billion per year of the drug and $1 billion or less is a big deal.

But since Incivek seems destined to be overtaken in the next few years, lower sales now aren't the end of the world. The company is sticking with its guidance of Incivek sales between $1.5 billion and $1.7 billion, which it's just barely on target to do when you factor in a $22 million decrease in wholesalers' inventory. And even if volume comes in a little short, a 7% price increase instituted April 1 should help.

In the longer term, the value of Vertex will be more about its cystic fibrosis pipeline than Incivek. And, like everyone else, it's developing next-generation hepatitis C drugs, so if it doesn't capture the patients now, perhaps there will be an option to pick them up later.

Vertex is beating the market by 234% since David Gardner and his team first recommended the stock in 2005. You can see his latest health-care find in the Fool's new free report, "Discover the Next Rule-Breaking Multibagger." Get your copy for free.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$56.32 (1.64%) $0.91
Abbott Laboratories Stock Quote
Abbott Laboratories
$128.70 (0.25%) $0.32
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$73.12 (-1.04%) $0.77
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$69.76 (0.13%) $0.09
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$204.46 (0.01%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.